Interviews for Fatigue in Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores why cancer-related fatigue occurs in people with non-small cell lung cancer (NSCLC) receiving immune therapy. Researchers aim to understand how this fatigue impacts daily life. Participants should have NSCLC that cannot be surgically removed and have experienced fatigue that hinders daily tasks.
As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on patients already receiving immunotherapy, so you may not need to change other medications, but it's best to check with the trial coordinators.
Is there any evidence suggesting that this treatment is likely to be safe for humans?
Studies have shown that immune checkpoint inhibitors (ICIs) can effectively treat non-small cell lung cancer (NSCLC). Research indicates that these treatments can extend patients' lives compared to traditional chemotherapy.
Regarding safety, ICIs are generally well-tolerated. Serious side effects are rare, with fewer than 4% of patients experiencing major issues like lung inflammation, liver problems, or skin rashes. Most people using ICIs do not encounter severe side effects.
Overall, ICIs are considered safe for many patients, though some may experience mild to moderate side effects. Discussing any concerns with a doctor is important when considering this treatment.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores how cancer-related fatigue impacts patients undergoing maintenance immunotherapy for non-small cell lung cancer (NSCLC). While most treatments for NSCLC focus on tumor reduction using methods like chemotherapy, radiation, or targeted therapies, this trial is unique in its focus on patient quality of life during treatment. By understanding fatigue in the context of immune checkpoint inhibitors, researchers hope to improve symptom management and enhance overall treatment experiences for patients. This approach could lead to more personalized care strategies that prioritize both efficacy and patient well-being.
What evidence suggests that this trial's treatments could be effective for cancer-related fatigue in NSCLC patients?
Research shows that immune checkpoint inhibitors (ICIs) can effectively treat non-small cell lung cancer (NSCLC). These treatments have helped many patients, though not all. For example, one study found that 17.1% of patients experienced tumor shrinkage, and 71.2% had their disease stabilize. In this trial, participants with NSCLC will receive ICIs, which enhance the immune system's ability to identify and attack cancer cells. While many with NSCLC benefit from ICIs, results can vary, and not everyone will experience the same improvements.36789
Who Is on the Research Team?
Dori Beeler, PhD
Principal Investigator
Atrium Health Levine Cancer
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Primary Interview
Participants complete the PROMIS® Fatigue-Short Form 7a and caregivers complete the CaTCoN form
Follow-up Interview
Participants are asked about changes in fatigue and views on physical activity
Follow-up
Participants are monitored for changes in fatigue and caregiver perspectives
What Are the Treatments Tested in This Trial?
Interventions
- Interviews
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Non-small cell lung cancer (NSCLC) patients treated with with immune checkpoint inhibitor.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
Atrium Health Levine Cancer Institute
Collaborator
Citations
Efficacy of immune checkpoint inhibitors in non-small cell ...
Immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in non-small cell lung cancer (NSCLC). However, only a minority of NSCLC patients ...
Clinical outcomes for immune checkpoint inhibitors plus ...
This study retrospectively assessed ICI-combination therapy outcomes in this molecular subset of NSCLC.
The real-world treatment characteristic and efficacy of ...
Here, we assessed the treatment characteristics and efficacy of ICIs in non-small cell lung cancer (NSCLC) using real-world data and evaluated ...
Safety and efficacy of immune checkpoint inhibitor ...
In our study of 111 patients with advanced NSCLC, ICI rechallenge resulted in an ORR of 17.1%, a DCR of 71.2%, and median PFS and OS values of ...
Real-world efficacy of immune checkpoint inhibitors in PD-L1 ...
Background: While immune checkpoint inhibitors (ICIs) have significantly improved outcomes for many non-small cell lung cancer (NSCLC) patients, ...
Risk and safety profile in checkpoint inhibitors on non-small ...
When used as first-line therapy, ICI have a 5-year survival rate of 23% compared to other treatments with survival below 16%. However, ...
Comparisons of adverse events associated with immune ...
Atezolizumab, a monoclonal antibody against PD-L1, has significantly improved lung cancer patients' survival rates [11]. Some studies have also ...
Efficacy and safety of immune checkpoint inhibitors in ...
ICIs are associated with a significant improvement in OS and PFS compared to chemotherapy in elderly patients with advanced NSCLC.
Adverse events of immunotherapy in non-small cell lung ...
The incidence of each serious adverse event was less than 4% in immune monotherapy. •. Serious pneumonitis, colitis, hepatitis and rash were more common in ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.